Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, Immunology, Antigen cross-presentation, DAMPs, immune checkpoint blockers, plasmacytoid dendritic cells, TLR signaling, tumor-infiltrating lymphocytes, clinical trial, ANTITUMOR IMMUNE-RESPONSES, RESISTANT PROSTATE-CANCER, CYTOTOXIC T-LYMPHOCYTES, APOPTOTIC TUMOR-CELLS, PHASE-I TRIAL, CROSS-PRESENTATION, SIPULEUCEL-T, ALPHA-GALACTOSYLCERAMIDE, INTRATUMORAL INJECTION, PANCREATIC-CANCER, C14/19/098#55221746, 1107 Immunology, 1112 Oncology and Carcinogenesis, 3204 Immunology, 3211 Oncology and carcinogenesis

Abstract:

Dendritic- cells (DCs) have received considerable attention as potential targets for the development of anticancer vaccines. DC-based anticancer vaccination relies on patient-derived DCs pulsed with a source of tumor-associated antigens (TAAs) in the context of standardized maturation-cocktails, followed by their reinfusion. Extensive evidence has confirmed that DC-based vaccines can generate TAA-specific, cytotoxic T cells. Nonetheless, clinical efficacy of DC-based vaccines remains suboptimal, reflecting the widespread immunosuppression within tumors. Thus, clinical interest is being refocused on DC-based vaccines as combinatorial partners for T cell-targeting immunotherapies. Here, we summarize the most recent preclinical/clinical development of anticancer DC vaccination and discuss future perspectives for DC-based vaccines in immuno-oncology.